Promising Treatments for Canker Sores — What's Coming (and What You Can Already Access)

TL;DR

The reasons canker sores are under-researched are real — but the pipeline isn't empty. Several treatments that either exist already or are actively in development deserve more attention than they get. This article separates them by time horizon: what you can access right now (but probably don't know about), what's in active research and likely within a decade, and what's scientifically grounded but still speculative. Evidence levels are rated honestly for each — most of the later-stage options are early and should be read accordingly.

Available Now, But Underutilized

These aren't future treatments. They exist. Most canker sore sufferers have never heard of them.

Compounded Amlexanox

Evidence level: Strong | Available now via prescription + compounding pharmacy

Amlexanox was the only drug ever specifically FDA-approved for recurrent aphthous stomatitis. It worked — RCTs showed it significantly reduced healing time and pain when applied early. Then, around 2019, the manufacturer discontinued Aphthasol commercially. Not because the drug failed. Because it wasn't profitable enough to keep making.

Here's what most sufferers don't know: amlexanox didn't disappear. It went to compounding pharmacies.

Compounding pharmacies prepare custom medications that aren't commercially available. A physician or dentist can write a prescription for amlexanox 5% paste, a compounding pharmacy can make it, and you can have the one drug with proven RAS-specific efficacy — the same formulation that ran in the RCTs — delivered to your door.

The mechanism is more sophisticated than most canker sore treatments. Amlexanox inhibits two kinases — IKKε (IκB kinase epsilon) and TBK1 (TANK-binding kinase 1) — that sit upstream of TNF-α and IL-6 production. These are the same inflammatory proteins that spike at ulcer sites and drive tissue destruction. By cutting off signaling to their production rather than mopping up the downstream proteins after they've already been released, amlexanox intervenes earlier and more specifically than a corticosteroid.

What to do: Ask your dentist or physician to write a prescription for amlexanox 5% paste and call around to compounding pharmacies in your area. Cost is typically $30–60 for a tube. Apply to the ulcer at the first prodromal tingle and multiple times daily — early application dramatically improves outcomes, as with all effective treatments.

L. reuteri Lozenges

Evidence level: Moderate | Available now, OTC

Probiotics for canker sores sounds like the kind of thing that belongs in the "no evidence" pile alongside baking soda and apple cider vinegar. Lactobacillus reuteri is the exception.

Two specific strains — DSM 17938 and ATCC PTA 5289 — are among the best-characterized probiotic strains in clinical research. Multiple small RCTs have found that lozenges containing these strains reduce the frequency and severity of aphthous outbreaks compared to placebo. The effect isn't dramatic, but it's consistent, and the mechanism is plausible in a way that makes it credible rather than coincidental.

The mechanism: L. reuteri produces reuterin, an antimicrobial compound that selectively disrupts gram-negative bacteria while leaving gram-positive commensal species intact. In the oral cavity, this shifts the microbiome away from the dysbiotic patterns associated with RAS — lower populations of protective Lactobacillus species and elevated gram-negative inflammatory species — and back toward a composition associated with mucosal health. L. reuteri also directly modulates mucosal immune activity, upregulating regulatory T-cells and reducing Th1 inflammatory signaling — the same aberrant immune pathway driving the T-cell attack in aphthous ulcers.

This is why L. reuteri is more mechanistically interesting than generic probiotics. It's not just "more bacteria are good." It's a specific strain acting on a specific microbiome imbalance through a characterized mechanism.

The catch: The two-strain combination (DSM 17938 + ATCC PTA 5289) is what has evidence. Generic lactobacillus supplements don't substitute. BioGaia makes oral health lozenges with this specific combination; the lozenge format matters because you need these strains in contact with the oral mucosa, not just passing through the gut.

Position this correctly: L. reuteri is not a replacement for B12, zinc, or SLS-free toothpaste if you haven't addressed those first. But for sufferers who've corrected known deficiencies and are still getting frequent outbreaks, it's a rational next-line intervention with an actual evidence base. See Probiotics for Canker Sores for the full breakdown.

Low-Level Laser Therapy (LLLT)

Evidence level: Moderate–Strong | Available now at dentists who offer it

Of everything on this page, LLLT has the strongest evidence and the lowest awareness gap. Multiple RCTs with consistent results. Near-immediate pain relief — often within minutes of treatment. Healing time reduced by roughly 50% in some trials. Essentially painless to receive. And almost nobody outside of oral medicine circles knows their dentist might offer it.

The mechanism: Low-level laser light — typically 670nm or 780nm wavelength — stimulates cytochrome c oxidase in mitochondria, which upregulates ATP production and cell repair activity in the irradiated tissue. Applied to the ulcer, it accelerates epithelial cell migration and proliferation (the repair phase), reduces local inflammatory mediators, and eliminates the exposed nerve stimulation that causes pain. This is photobiomodulation — not burning or ablation, but stimulation of the cell's own repair machinery.

The clinical translation: patients typically report a significant reduction in pain within an hour of treatment, and ulcers that would otherwise last 7–10 days often resolve in 3–5 days. For major aphthous ulcers, where the untreated timeline is 2–6 weeks, the benefit is proportionally larger.

The barrier: Not every dental office has a laser, and among those that do, not all use it for aphthous ulcers. It requires knowing to ask. Cost is typically $50–150 per session and not covered by dental insurance, but for a patient in the acute pain of an active ulcer, the math is compelling. For home use between dental visits, consumer LLLT devices at 660nm have emerged as an accessible alternative — the evidence base is for clinical equipment, but the photobiomodulation principle translates.

In Active Research (5–15 Years)

These treatments aren't available yet, but the research is real, active, and addresses mechanistic gaps that current options don't.

Bioadhesive Nanogel Drug Delivery

Evidence level: Weak (preclinical/early research)

The problem with existing canker sore treatments isn't always the drug — it's the delivery. Apply a paste to wet oral tissue and it washes away within minutes. Apply it once a day and you've covered maybe 5% of the time the ulcer needs treatment. The drug works; the physics of the mouth defeats it.

Nanoliposomal delivery systems are designed specifically to solve this. Researchers have loaded amlexanox into lipid-based nanoparticles coated with bioadhesive polymers — compounds that bind to mucin, the glycoprotein layer over oral tissue — creating a formulation that adheres to the mucosal surface and releases the drug slowly over hours rather than minutes.

In preclinical studies, nanoliposomal amlexanox demonstrates significantly higher mucosal drug concentrations, longer residence time at the ulcer site, and better tissue penetration than conventional paste. The version currently in development is designed to be applied once at the prodromal stage and maintain therapeutic drug levels through the early ulcerative phase — potentially aborting outbreaks with a single application.

This isn't a new drug. It's dramatically better delivery of a drug we already know works. That's a less heroic story than a novel molecule, but it's faster and lower-risk to develop — which is why it's more likely to actually arrive.

Bacteriophage Therapy

Evidence level: Weak (early research)

The oral microbiome in RAS patients isn't random noise. Studies have found consistent compositional differences: reduced populations of protective Lactobacillus species, altered Streptococcus profiles, and elevated counts of specific gram-negative bacteria associated with mucosal inflammation. This dysbiosis doesn't cause RAS on its own, but it contributes to the immune dysregulation that allows ulcers to form and prolongs healing.

Bacteriophages are viruses that infect bacteria — specific strains infect specific bacterial species with precision that no antibiotic can match. Unlike probiotics, which add bacteria and hope they establish, phage therapy removes the specific problematic species from the microbiome without disturbing the commensal population around them.

Applied to the oral cavity, a targeted bacteriophage therapy could correct the dysbiotic shifts associated with RAS — not by treating the immune system directly, but by removing the microbiome signal that's destabilizing it. This is early-stage, and the technical challenges of phage-mucosal delivery are significant. But the conceptual framework is compelling and the field is moving fast, driven by antibiotic-resistance research with far larger commercial stakes than canker sores. The relevant phage research will arrive from adjacent conditions and get applied here.

Targeted IKKε/TBK1 Inhibitors

Evidence level: Weak (research phase)

Amlexanox's mechanism — inhibiting IKKε and TBK1 to cut off upstream TNF-α and IL-6 production — is the right mechanism for RAS. The problem with amlexanox itself is that it was a repurposed compound, originally developed for something else, and its kinase inhibition activity was somewhat serendipitously discovered. It's effective but not purpose-built.

A new generation of IKKε/TBK1 inhibitors is in development — designed from scratch for selectivity, potency, and mucosal delivery. These compounds would have higher affinity for the target kinases, cleaner pharmacological profiles (fewer off-target effects), and ideally be engineered for topical mucosal delivery from the start rather than adapted from a systemic drug.

Think of this as amlexanox done correctly on the first attempt. The commercial path remains challenging for the same reasons the entire RAS field faces — the treatment population is large but the willingness to pay is limited — but if these inhibitors reach development for larger indications (Behçet's disease, oral mucositis in cancer patients), RAS will benefit from the overspill.

Longer-Term — Speculative but Scientifically Grounded

These are further out, have more uncertainty, and are included because the underlying science is real and worth understanding — not because a clinical product is imminent.

HSP60 Mucosal Tolerance Induction

Evidence level: Weak (hypothesis with mechanistic support)

This is the most intellectually interesting entry on the list, and almost nothing written for a general audience explains it clearly.

Start with the problem: canker sores are the immune system attacking the lining of your own mouth. Why? The leading mechanistic hypothesis involves molecular mimicry — the immune system attacking a human protein because it looks too much like a bacterial protein it was trained to fight.

Here's the specific mechanism. Bacteria that colonize the mouth — particularly streptococcal species — express a protein called heat shock protein 65 (HSP65). The immune system learns to recognize and attack HSP65 as a bacterial marker. This is normal and useful immunity. The problem: human oral mucosal cells also express a closely related protein, heat shock protein 60 (HSP60), particularly under conditions of cellular stress — exactly the conditions present in traumatized, nutrient-depleted, or hormonally stressed oral tissue. The proteins are similar enough that an immune system sensitized to bacterial HSP65 cross-reacts with human HSP60 in the mouth lining.

In other words: the immune system isn't malfunctioning randomly. It's attacking the wrong target because the right target and the wrong target look almost identical. Stress and nutritional depletion increase HSP60 expression, which is why those are canker sore triggers — they don't directly cause ulcers, they increase the expression of the protein the immune system is already primed to attack.

The therapeutic implication is compelling. Allergy immunotherapy works by repeatedly exposing the immune system to small doses of an allergen, gradually inducing tolerance — training the immune response to stop overreacting. Mucosal tolerance induction with HSP60 antigen follows the same logic: repeated low-dose oral exposure to the antigen trains the immune system to tolerate HSP60-expressing mucosal cells rather than attacking them. This approach has been explored in animal models and in small early-stage human research.

This is genuinely far out — tolerance protocols take years of development and careful safety validation. But it's the first hypothesis that offers a path toward something resembling a cure rather than better symptom management, and the underlying science is too coherent to dismiss.

Oral Microbiome Transplant

Evidence level: Weak (hypothesis)

Fecal microbiome transplant (FMT) is now FDA-approved for recurrent Clostridium difficile infection. The concept: a dysbiotic gut microbiome causing chronic disease can be reconstituted by transplanting stool from a healthy donor. FMT for C. diff achieves cure rates that no antibiotic reaches.

The conceptual framework is identical for the oral cavity. If RAS is associated with a consistently dysbiotic oral microbiome — and the evidence suggests it is — then transplanting oral microbiome material (saliva, swabs) from a consistently RAS-free donor into a chronic RAS sufferer could theoretically reconstitute a protective microbiome. The oral cavity is a substantially less complex microbial environment than the gut, which in theory makes the transplant challenge more tractable, not less.

This doesn't exist as a clinical treatment. There are no published RCTs. The barriers — donor screening, colonization durability, competitive exclusion by the recipient's existing flora — are real and unsolved. But three years ago, saying "FDA-approved FMT" would have sounded equally speculative, and it's now a real treatment. The analogous framework for the oral microbiome is worth planting as a concept.

A Note on Timelines

None of these timelines are guarantees. Medical research is iterative, unpredictable, and heavily dependent on funding dynamics that, as explored in Why Aren't Canker Sores Solved?, systematically underinvest in this condition. The "5 years" treatments — amlexanox via compounding, L. reuteri, LLLT — are real and accessible today. The medium-term options are backed by real published research but face commercialization barriers. The speculative section is honest speculation.

What's worth taking away: the scientific understanding of RAS has advanced considerably. The mechanisms are increasingly clear, the targets are increasingly identified, and the borrowed advances from immunology, microbiome research, and drug delivery science are arriving faster than canker sore-specific funding would have produced on its own. The gap between "what we know" and "what we can do" is narrowing.

In the meantime, the best currently-available options — compounded amlexanox, corticosteroid gels, LLLT, Debacterol, and micronutrient correction — are meaningfully better than most sufferers realize.